52 related articles for article (PubMed ID: 8452352)
1. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.
Chimata M; Nagase M; Suzuki Y; Shimomura M; Kakuta S
Antimicrob Agents Chemother; 1993 Feb; 37(2):229-33. PubMed ID: 8452352
[TBL] [Abstract][Full Text] [Related]
2. Meropenem-Induced Delirium in a Hemodialysis-Dependent Adolescent Girl.
Tabulov C; Montoya M; Panzarino V
Clin Pediatr (Phila); 2024 Jun; 63(5):594-598. PubMed ID: 37382344
[No Abstract] [Full Text] [Related]
3. A Systematic Review of the Effect of Therapeutic Drug Monitoring on Patient Health Outcomes during Treatment with Carbapenems.
Luxton TN; King N; Wälti C; Jeuken LJC; Sandoe JAT
Antibiotics (Basel); 2022 Sep; 11(10):. PubMed ID: 36289971
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools.
Weinelt FA; Stegemann MS; Theloe A; Pfäfflin F; Achterberg S; Weber F; Dübel L; Mikolajewska A; Uhrig A; Kiessling P; Huisinga W; Michelet R; Hennig S; Kloft C
Antibiotics (Basel); 2022 Jun; 11(6):. PubMed ID: 35740164
[TBL] [Abstract][Full Text] [Related]
5. Anti-infective Medicines Use in Children and Neonates With Pre-existing Kidney Dysfunction: A Systematic Review.
Minotti C; Barbieri E; Doni D; Impieri C; Giaquinto C; Donà D
Front Pediatr; 2022; 10():868513. PubMed ID: 35558367
[TBL] [Abstract][Full Text] [Related]
6. Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing-A Translational Example for Intensive Care Units.
Weinelt FA; Stegemann MS; Theloe A; Pfäfflin F; Achterberg S; Schmitt L; Huisinga W; Michelet R; Hennig S; Kloft C
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959409
[TBL] [Abstract][Full Text] [Related]
7. The Case for Intermittent Carbapenem Dosing in Stable Haemodialysis Patients.
Ho V; Tay F; Wu JE; Lum L; Tambyah P
Antibiotics (Basel); 2020 Nov; 9(11):. PubMed ID: 33207584
[TBL] [Abstract][Full Text] [Related]
8. Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia.
Thémans P; Marquet P; Winkin JJ; Musuamba FT
Drugs R D; 2019 Jun; 19(2):177-189. PubMed ID: 31090024
[TBL] [Abstract][Full Text] [Related]
9. Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts.
Hamanoue S; Suwabe T; Ubara Y; Kikuchi K; Hazue R; Mise K; Ueno T; Takaichi K; Matsumoto K; Morita K
BMC Nephrol; 2018 Oct; 19(1):272. PubMed ID: 30340529
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.
Braune S; König C; Roberts JA; Nierhaus A; Steinmetz O; Baehr M; Kluge S; Langebrake C
Crit Care; 2018 Jan; 22(1):25. PubMed ID: 29382394
[TBL] [Abstract][Full Text] [Related]
11. Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.
Diep JK; Jacobs DM; Sharma R; Covelli J; Bowers DR; Russo TA; Rao GG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872078
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Mazuski JE; Gasink LB; Armstrong J; Broadhurst H; Stone GG; Rank D; Llorens L; Newell P; Pachl J
Clin Infect Dis; 2016 Jun; 62(11):1380-1389. PubMed ID: 26962078
[TBL] [Abstract][Full Text] [Related]
13. An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis.
Wiesholzer M; Pichler P; Reznicek G; Wimmer M; Kussmann M; Balcke P; Burgmann H; Zeitlinger M; Poeppl W
Antimicrob Agents Chemother; 2016 May; 60(5):2790-7. PubMed ID: 26902765
[TBL] [Abstract][Full Text] [Related]
14. Outcome evaluation of an intervention to improve the effective and safe use of meropenem.
Yagi Y; Okazaki M; Higaki H; Nakai M; Hirata A; Miyamura M
Int J Clin Pharm; 2014 Jun; 36(3):648-56. PubMed ID: 24748508
[TBL] [Abstract][Full Text] [Related]
15. Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.
Zhanel GG; Simor AE; Vercaigne L; Mandell L;
Can J Infect Dis; 1998 Jul; 9(4):215-28. PubMed ID: 22346545
[TBL] [Abstract][Full Text] [Related]
16. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
Bilgrami I; Roberts JA; Wallis SC; Thomas J; Davis J; Fowler S; Goldrick PB; Lipman J
Antimicrob Agents Chemother; 2010 Jul; 54(7):2974-8. PubMed ID: 20479205
[TBL] [Abstract][Full Text] [Related]
17. Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
Mallalieu NL; Lennon S; Liu M; Kirkpatrick C; Robson R; Luedin E; Davies BE
Antimicrob Agents Chemother; 2008 Jul; 52(7):2360-6. PubMed ID: 18443123
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.
Thalhammer F; Hörl WH
Clin Pharmacokinet; 2000 Oct; 39(4):271-9. PubMed ID: 11069213
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics of the carbapenems: clinical implications.
Mouton JW; Touzw DJ; Horrevorts AM; Vinks AA
Clin Pharmacokinet; 2000 Sep; 39(3):185-201. PubMed ID: 11020134
[TBL] [Abstract][Full Text] [Related]
20. Meropenem: a review of its use in patients in intensive care.
Hurst M; Lamb HM
Drugs; 2000 Mar; 59(3):653-80. PubMed ID: 10776838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
